Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521917

SCHEMBL1521917

SCHEMBL1521917

CNc1cc2c(cn1)CN(c1ccc(F)c(NC(=O)Nc3cncc(C(F)(F)F)c3)c1)C(=O)N2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 14/20 0.40
▸ BIRC3 Q13489 1/20 0.37
▸ MALT1 Q9UDY8 1/20 0.37
▸ BRAF P15056 5/20 0.36
▸ MAPK14 Q16539 4/20 0.36
▸ TNNI3K Q59H18 4/20 0.36
▸ BACE2 Q9Y5Z0 1/20 0.36
▸ PDGFRB P09619 2/20 0.35
▸ ABL1 P00519 2/20 0.35
▸ RIPK2 O43353 1/20 0.35
▸ KIT P10721 2/20 0.35
▸ PDGFRA P16234 2/20 0.35
▸ LCK P06239 1/20 0.35
▸ FES P07332 1/20 0.35
▸ RET P07949 1/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ SRC P12931 1/20 0.35
▸ FLT1 P17948 1/20 0.35
▸ FGFR3 P22607 1/20 0.35
▸ EPHA3 P29320 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521993 0.90 KDR (0.39) KDRBIRC3MALT1BRAFMAPK14
SCHEMBL1521678 0.88 KDR (0.40) KDRBIRC3MALT1BRAFMAPK14
SCHEMBL1521765 0.87 KDR (0.40) KDRBIRC3MALT1BRAFMAPK14
SCHEMBL1521638 0.85 BRAF (0.47) KDRBRAFMAPK14PDGFRBABL1
SCHEMBL1521380 0.83 KDR (0.36) KDRBRAFKITPDGFRAFGFR1
SCHEMBL1521668 0.81 KDR (0.45) KDRBRAFMAPK14TNNI3KRIPK2
SCHEMBL1521794 0.81 MAPK14 (0.44) KDRBRAFMAPK14ABL1RAF1
SCHEMBL1521817 0.80 BRAF (0.40) KDRBRAFMAPK14PDGFRBABL1
SCHEMBL1521766 0.80 TNK2 (0.42) KDRBRAFMAPK14PDGFRBABL1
SCHEMBL1521722 0.80 KCNJ6 (0.48) BRAFMAPK14NTRK3RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 KDR 500/4885BIRC3 861/4885MALT1 344/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 KDR 500/4885BIRC3 861/4885MALT1 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.